Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-LineHelicobacter pyloriEradication: A Randomized Controlled Trial
| Autor: | Masayuki Miyajima, Daisuke Kubota, Naoki Tanaka, Ryujiro Imai, Kendo Kiyosawa, Hiromitsu Mori, Takefumi Kimura, Toru Fujisawa, Shuichi Wada, Yoshiaki Matsuda, Koujiro Tokutake, Masafumi Maruyama, Akira Horiuchi |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
Vonoprazan Pharmacology Gastroenterology law.invention 0302 clinical medicine Japan Randomized controlled trial law Clarithromycin Single-Blind Method Aged 80 and over Sulfonamides biology General Medicine Middle Aged Anti-Bacterial Agents Treatment Outcome Rabeprazole 030220 oncology & carcinogenesis Drug Therapy Combination Female 030211 gastroenterology & hepatology medicine.drug Adult medicine.medical_specialty Article Subject Lansoprazole Helicobacter Infections 03 medical and health sciences Internal medicine medicine Humans Pyrroles lcsh:RC799-869 Aged Helicobacter pylori Hepatology business.industry Amoxicillin Proton Pump Inhibitors biology.organism_classification Regimen Clinical Study lcsh:Diseases of the digestive system. Gastroenterology business |
| Zdroj: | Canadian Journal of Gastroenterology and Hepatology, Vol 2017 (2017) Canadian Journal of Gastroenterology & Hepatology |
| ISSN: | 2291-2797 2291-2789 |
| DOI: | 10.1155/2017/4385161 |
| Popis: | Background. A new agent, potassium-competitive acid blocker vonoprazan (VPZ) has potent acid-inhibitory effects and may offer advantages over conventionalH. pylorieradication therapies. We aimed to compare the eradication rate between VPZ-based treatment and PPI-based one.Methods. This randomized controlled trial was designed to assign 141 patients withH. pylori-positive gastritis to VPZ group (VPZ 20 mg, amoxicillin 750 mg, and clarithromycin 200 or 400 mg twice daily for 7 days) or PPI group (rabeprazole 20 mg or lansoprazole 30 mg, amoxicillin 750 mg, and clarithromycin 200 or 400 mg twice daily for 7 days). Primary endpoints were eradication rates and adverse events.Results. Seventy of 72 patients in VPZ group and 63 of 69 patients in PPI group completed the treatment after 7 days. The eradication rate was significantly higher in VPZ group than PPI group by intention-to-treat analysis (95.8% versus 69.6%,P=0.00003, 95% confidence interval [CI] 88.3-99.1% versus 57.3-80.1%) and per-protocol analysis (95.7% versus 71.4%,P=0.0002, 95% CI 88.0-99.1% versus 58.7-82.1%). The incidence of adverse events was not different between the groups (26.3% in VPZ group versus 37.7% in PPI group,P=0.15).Conclusion. VPZ-based regimen is more useful than that PPI-based regimen as a first-lineH. pylorieradication therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text